Biogen quarterly results top estimates despite complex launch of new Alzheimer's treatmentMarket Watch • 11/08/23
Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses MountInvestors Business Daily • 11/08/23
Countdown to Biogen Inc. (BIIB) Q3 Earnings: A Look at Estimates Beyond Revenue and EPSZacks Investment Research • 11/06/23
Biogen Inc. (BIIB) Rises But Trails Market: What Investors Should KnowZacks Investment Research • 10/30/23
Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's TreatmentInvestors Business Daily • 10/26/23
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in studyCNBC • 10/25/23
Biogen and Eisai release new Alzheimer's drug data that may support wider uptakeMarket Watch • 10/25/23
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On AlzheGlobeNewsWire • 10/25/23
New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's DiseaseGlobeNewsWire • 10/25/23
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 MeetingGlobeNewsWire • 10/19/23
Wall Street Analysts See a 25.44% Upside in Biogen Inc. (BIIB): Can the Stock Really Move This High?Zacks Investment Research • 10/13/23